Teva Canada announces availability of Aermony RespiClick™, an innovative new device for the treatment of bronchial asthma

Aermony RespiClick™ (fluticasone propionate inhalation powder), available in three dose options

  • Asthma is a chronic, lifelong condition without a cure that can cause life-threatening symptoms and affects 3.8 million Canadians.1–3
  • Although inhaled medication is the cornerstone of therapy, incorrect inhaler technique is common—indicating that device selection is important and can affect outcomes.4

MONTRÉAL, Oct. 5, 2020 /CNW/ - Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., today announced product availability of Aermony RespiClick™, indicated for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and older5 and offered in a simple-to-use inhaler. 

Aermony RespiClick™ (fluticasone propionate inhalation powder) is packaged in an innovative device with features designed to simplify the administration of inhaled therapy and reduce patient error and confusion. One key feature is the innovative cap that integrates the opening and priming steps—thereby minimizing patients' coordination errors. A "click" sound confirms that the dose is ready, which helps support patient confidence in their dose and device.5

"Devices play a central role in the success of asthma therapy since the evidence clearly demonstrates an important association between inhaler errors and suboptimal asthma control.1 It stands to reason that a device that is simple to use may also minimize errors that may lead to poor asthma control," said Dr. Anthony D'Urzo, a practising family physician and researcher at the University of Toronto. "Aermony RespiClick™ has desirable 'user-friendly' features that make it a welcome addition for patients who require maintenance therapy with a medication like fluticasone propionate."

"We're pleased that Aermony RespiClick™ is now available in Canada. With this innovative method of delivery of medication, respirologists and asthma patients will experience the simplified administration features the RespiClick™ device has to offer," said Christine Poulin, general manager of Teva Canada. "Aermony RespiClick™ is a meaningful expansion of our offerings in respirology, which currently include both proprietary and generic products."

Fluticasone propionate, the active ingredient in Aermony RespiClick™, has been extensively studied in clinical trials and has been available in the Canadian market for 27 years, since 1993.2 Aermony RespiClick™ will enter the market offering a price advantage compared to the branded fluticasone propionate inhalation powder and will come in three dose options:

  • 55 mcg per actuation 
  • 113 mcg per actuation 
  • 232 mcg per actuation 

Patients using Aermony RespiClick™ take one inhalation twice daily at the same time every day, approximately 12 hours apart.5

About bronchial asthma

Asthma is a chronic inflammatory disease of the airway that causes trouble breathing.3 It is a lifelong condition without a cure that affects 3.8 million people in Canada.3,4,6 Six out of ten people do not have control of their disease.6 The cause of asthma remains unknown, but it is not contagious and appears to be caused by both hereditary and environmental factors.6An attack is often triggered by something in the environment, such as dust mites, animals, pollens, and viral infections, but the triggers are individual to each patient.7 An attack can happen suddenly and be life threatening.8 Inhalers are the cornerstone of treatment, but, despite the potential benefits of inhaler therapy, evidence suggests that many patients do not use their inhalers correctly.9 Therefore, device selection may play an important role in an individual patient's success on therapy.

About Aermony RespiClickTM

Aermony RespiClick™ is indicated for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and older. Aermony RespiClick™ is available in three dose options: 55 mcg, 113 mcg, and 232 mcg per actuation. It is dosed as one inhalation twice daily at the same time every day, approximately 12 hours apart.

Helping improve the lives of Canadians

At Teva, we care deeply about the well-being of the patients, caregivers, and communities that rely on us. We serve 200 million people every day, with a promise to help them take better control of their health. From our role as a global leader in generic and brand-name medicines to the innovative solutions we create for our healthcare partners, we offer a unique perspective on health—here in Canada and around the world.

About Teva Canada 

Teva Canada, headquartered in Toronto, has provided affordable healthcare solutions to Canadians for over 50 years, building their trust one prescription at a time with now more than 217,00010 prescriptions filled each day with our products. Originally Novopharm Limited, Teva Canada specializes in the development, production, and marketing of high-quality generic prescription pharmaceuticals and, through our branded division, focuses on a diverse line of innovative products in a variety of therapeutic areas. Teva Canada employs more than 900 professionals, had sales of nearly $1.3 billion10 in 2019, and markets more than 385 products in 1,000 SKUs10 in Canada. We are a proud subsidiary of Teva Pharmaceutical Industries Ltd. Learn more at www.tevacanada.com.

About Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people's lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

____________________________________

SKU: stock-keeping unit
1.Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19:10.
2.Health Canada Drug Product Database. Search for: fluticasone propionate. Available from: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp. Last accessed: September 1, 2020.
3.Asthma Canada. Understanding asthma: what is asthma? Available from: https://asthma.ca/what-is-asthma/. Last accessed: September 1, 2020.
4.Asthma Canada. Frequently asked questions. Available from: https://asthma.ca/get-help/understanding-asthma/frequently-asked-questions/. Last accessed: September 1, 2020.
5.Aermony RespiClick™ Product Monograph. Teva Canada. December 14, 2018. 
6.Asthma Canada. Who gets asthma? Available from: https://asthma.ca/get-help/understanding-asthma/. Last accessed: September 1, 2020.
7.Asthma Canada. Common asthma triggers. Available from: https://asthma.ca/get-help/asthma-triggers/. Last accessed: September 1, 2020. 
8.Asthma Canada. What is an asthma attack? Available from: https://asthma.ca/get-help/living-with-asthma/asthma-attacks/. Last accessed: September 1, 2020.
9.Murphy A. How to help patients optimise their inhaler technique. Pharm J. 2016;297(7891). DOI: 10.1211/PJ.2016.20201442.
10.Source: IQVIA CDH & Compuscript MAT. April 2020.

SOURCE Teva Canada

Mid-Point Report Card: pan-Canadian Generics Initiative Has Delivered Close to $2-Billion in Savings

TORONTO, Oct. 5, 2020 /CNW/ - Canadians have saved close to $2-billion in prescription drug costs during the first half of the five-year agreement between the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association (CGPA).

As part of the agreement – which includes federal government drug plans and all of Canada's provinces and territories except Quebec – the prices of nearly 70 of the most commonly prescribed drugs in Canada were reduced by 25 to 40 percent effective April 1, 2018, resulting in overall discounts of up to 90 percent off the price of their brand-name equivalents. 

"Canada's generic pharmaceutical industry continues to make an essential contribution to affordable patient care in Canada," said Jim Keon, President of the CGPA. "We are, however, growing concerned about the impact of years of price cuts on the sustainability of domestic manufacturing capacity, and the ongoing continuity of Canada's supply of prescription medicines." 

Data released by the Patented Medicine Prices Review Board (PMPRB) shows that, since 2007, the average price of generic prescription medicines in Canada has fallen by nearly 60 percent, with prices of some of the top-selling generics dropping by an average of 80 percent. 

These massive price cuts have resulted in new cost structures for generic pharmaceutical manufacturers, which has led to more of Canada's drug supply coming from lower-cost jurisdictions such as China and India.

"COVID-19 has been a wakeup call for governments, healthcare professionals and the public about Canada's increasing reliance on imports," Keon said. "Moving forward there must be a recognition that sustainable pricing levels are needed to maintain the continuity of supply for Canadians."

With nearly three quarters of all prescriptions in Canada being filled with generic prescription medicines, Canada's supply of prescription medicines rests largely with the generic pharmaceutical industry. 

"Canadians have continued to have access to both their regular day-to-day medicines and the products needed to treat patients with COVID-19 during the pandemic as a result of the tireless efforts of generic pharmaceutical companies," said Keon. "The pandemic has also exposed several areas where improvements can be made to help secure a sustainable supply of prescription medicines for Canadians."

In June 2020, CGPA released its Blueprint for a Sustainable Supply of Prescription Medicines for Canadians that identifies measures to strengthen the domestic pharmaceutical industry and Canada's place in the international supply chain to ensure Canadians have a secure and consistent supply of prescription medicines.

About the Canadian Generic Pharmaceutical Association
The Canadian Generic Pharmaceutical Association (CGPA) represents Canada's generic pharmaceutical industry. The industry plays an important role in controlling health-care costs in Canada. Generic drugs are dispensed to fill 73 percent of all prescriptions but account for account for less than 20 percent of the $32-billion Canadians spend annually on prescription medicines.

SOURCE Canadian Generic Pharmaceutical Association

Gripping Account of Suicide Attempt and Recovery Aims to Break the Stigma Surrounding Mental Health

New York NY, October 5, 2020 — Mark Henick is one of North America’s foremost advocates for mental health. His powerful TEDx talk, Why We Choose Suicide, is among the most watched in the world and shares his unforgettable account of standing on an overpass and letting go. He is one of the lucky few to plunge into the seemingly unforgiving darkness and somehow awaken to the hopeful light of day.  

He shares his vital, triumphant story of perseverance and recovery in So-Called Normal: A Memoir of Family, Depression and Resilience, in which he vividly recounts his heart-pounding moments on the wrong side of the railing on a crumbling, concrete overpass. 

Henick’s near-death experience that night would alter his emotional orbit just enough that his exit from a psychiatric ward following that suicide attempt in 2003 would be his last. His transformation didn’t happen overnight — it was a gradual process punctuated with new challenges and setbacks — but slowly, his patterns reversed and he began a profound, “upward” spiral toward recovery.

So-Called Normal chronicles Henick’s youth and the events that led to that fateful night on the bridge and the experiences and transformation that followed. It is a vivid and personal account of a boy who had to deal with the breakdown of his parents’ marriage, an abusive stepfather, bullying and trauma — all while trying to navigate his progressively worsening mental health. In the backdrop is a community that didn’t talk about mental illness, one where silence and maintaining the comforts of “normal” was paramount. 

So-Called Normal is not a “misery memoir” about suicide — it’s a gripping, inspirational story of survival that has already touched the hearts of many, including television personality Rosie O’Donnell.

“Mark Henick is a powerful storyteller. His vivid account of his early years as a depressed, suicidal teenager is a page-turner. So-Called Normal is beautifully written, heart-wrenching, and hopeful. Necessary reading for anyone who wants a peek inside the mind of someone who journeyed through mental illness and found hope on the other side,” O’Donnell said.

Author Mark Henick’s TEDx talk about being saved from death by a stranger is one of the most watched in the world and has been viewed millions of times. His search for “the man in the brown jacket” whose bravery and strong arms kept him from falling to his death went viral around the world (and was successful!). Henick has been on television and radio and has written many articles on mental health. He has hosted more than 60 intimate conversations about mental health with notable public figures and celebrities on his podcast, So-Called Normal, and has executive produced and hosted the Living Well podcast for Morneau Shepell. Henick has served on the board of directors for the Mental Health Commission of Canada, and was the president of a provincial division of the Canadian Mental Health Association — the youngest person in either role. He has worked as a frontline clinician, a program manager and the national director of strategic initiatives for CMHA. Currently the CEO and principal strategist for Strategic Mental Health Consulting, Mark Henick is in high demand as an international keynote speaker on mental health recovery.

To watch Henick’s powerful TEDx talk, please visit https://youtu.be/D1QoyTmeAYw. For more information, please visit www.markhenick.com or connect with the author on the following social media sites: www.facebook.com/markhenick/; https://twitter.com/markhenick; and www.youtube.com/markhenick.

So-Called Normal: A Memoir of Family, Depression and Resilience

Publisher: HarperCollins

Release Date: January 12, 2021

ISBN-10: 1443455032 

ISBN-13: 978-1443455039

Available from Amazon.com, BarnesandNoble.com, Audible and others 

Sleep, Men and Glutamine. Honestly this podcast topics seem to be adding up to 3 things Motivation, Men and Health. It only took me 18 episodes to find my fav topics and finalize them! Enjoy! And feel free to use my code for any products on HD Muscle that I suggest. They really are the best. Code: trainitright xoxo enjoy this weeks podcast!

REVOLUTIONARY NEW ITALIAN THERMAL PAINT BRAND BISATEN™ COMES TO CANADIAN MARKET

Winterize & Beautify Your Home With Stylish, Energy-Saving “Green” Interior Paint

Nashville, TN, October 1, 2020 --- Bisaten™ Thermo Paint & Primer, manufactured in Italy and brand new to the North American market, is fast making inroads into the trade and consumer press, gaining praise from top interior decorators and builders. Bisaten has so far been featured in prestigious KBB Business: Kitchens & Baths, Green Home Builder, Old House Journal and most recently, was a Product Spotlight in the Canadian publication Home Improvement Retailing.

With average winter temperatures ranging from 19.4 degrees in Toronto to as low as 12-16 degrees in the prairie provinces and Quebec, Canadians spend major money keeping homes and buildings warm and habitable during colder months. 

Bisaten Thermo is patented: it is the only interior paint currently on the market with an R-value, which measures how efficiently it insulates and prevents heat from escaping through walls and ceilings. Bisaten paint & primer saves up to 26% in energy bills per month thanks to its special formulation with 3M technology. 

“As an interior decorator, I’m always looking for solutions for my clients that match their need for energy conservation with their desire for a beautiful quality interior paint” says American decorator Lisa Crandall. “I recently completed a home reno for a client using Bisaten in several fabulous colors. She was amazed that it took care of her mold and condensation issues, is saving her money every month and still looks incredibly smooth and pretty!” 

This extra-durable, easy-to-apply washable paint is specially formulated to provide a reliable, experience for professional painters, contractors and DIY enthusiasts. In response to the needs of our planet and the health and safety of humans and animals, it is completely non-toxic, free of volatile organic compounds and packaged in recyclable containers. This unique insulating product is available in a range of gorgeous colors inspired by the stunning Italian countryside and coastline.

Bisaten™ Thermal Paint & Primer’s immediate success in the US market is predicated on a dream come true scenario for smart consumers, matching practicality with gorgeous interiors. It is now available to order in Canada via www.bisaten.us, and in response to demand, the company is actively seeking regional Canadian distributors. Bisaten will soon be carried in major hardware chains across North America.  

AnnClaire Media, LLC is a full-service PR, branding and content agency based in Tennessee.

Dr. David Shokrian: Cosmetic Surgery is Booming in the Age of COVID  

With more people staying at home than ever before over the past few months, Dr. David Shokrian, a renowned NYC plastic surgeon, has seen something unexpected.
“Post-COVID, there has been a big surge in cosmetic plastic surgery,” says Shokrian, owner of Millennial Plastic Surgery. “Everything from Botox and fillers to liposuction and tummy tucks. Even though people are going out less, they still want to look their best.”
There are multiple reasons for this. One of the factors that patients often bring up to Dr. Shokrian is displeasure with the way they look on Zoom calls. During a time when a large number of people are taking to the internet — to do business, to socialize with friends and family, and even to date — video calls can highlight features that they’d prefer to have fixed. 
Another factor? With gyms closed and stress levels at an all-time high, people have gotten out of their usual fitness routines and are starting to notice the effects. Cosmetic surgery offers them a way to look and feel their best — and with fast results. 
The past several months have found people spending less time and money on travel, concerts, and dining out. Many folks have found themselves at home with money to spend on improving themselves with procedures such as body contouring or facial rejuvenation. An added plus? All that time at home gives them ample time and privacy to recover. 
Dr. Shokrian, a pioneer in fat grafting, body contouring, and facial rejuvenation, has also noticed a big emotional shift in his patients since the pandemic began. 
“The coronavirus crisis has changed the way many people approach life and the way they feel about themselves,” he said. “This pandemic has made people re-examine and re-prioritize. One of the things I’m hearing from so many patients is ‘Life is short. I want to live my best life now.’”
As a plastic surgeon, Dr. David Shokrian is proud to be able to help them do that. From breast augmentations and butt lifts to face lifts, lip augmentation, and rhinoplasty, he uses the latest cutting-edge technology to assist patients in getting the results they want. Best of all, he’s pleased to be able to do it in a manner that keeps everyone safe — offering at-home virtual consultations and employing the use of temperature checks and face masks for in-office visits.
“I’ve seen the immense psychological boost that cosmetic plastic surgery can have for my patients even during normal times,” Dr. Shokrian said. “During a time that has been challenging for so many, we’re pleased that patients are coming to us to take steps to becoming the best version of themselves.” 

Parler Strategic Investor Continues to Expose Facebook Tyranny


LAS VEGAS, NEVADA - Parler, the people-driven free speech platform, today released a statement from Strategic Investor and COO Jeffrey Wernick berated Facebook as the tech giant intensifies efforts to control information flow surrounding the November 3 election.

Wernick, a longtime critic of Facebook’s abusive data practices and public deception, addressed a recent announcement that the tech publisher will ban ads that question the election results or raise issues of potential voter fraud.

Parler, in a pledge released last week, affirmed its commitment to a free flow of information related to the election, including unfettered access for candidates, election workers, political parties, journalists, and watchdogs to share information with the public.

“Facebook’s move to block ads alleging irregularities with the vote is just another part of their plan to control the dissemination of information and, ultimately, tell Americans what they should think,” said Mr. Wernick. “First they told us they would brownout posts from sources they do not like. Now, they say they will block efforts to counter this content curation via purchasing access to News Feeds, whenever the content at issue contradicts Facebook’s chosen narrative. While private businesses may have the right to do these kinds of things, we have the right—particularly during an election season—to judge this as more technoauthoritarianism. 

“As usual, Facebook tries to use nice words to make their authoritarianism sound benign. Their polished spokespeople talk about preventing reports of ‘isolated incidents’ from damaging the perception of election integrity. This spin is nothing short of Orwellian language manipulation.

“Language matters. Truth matters. All incidents are by definition ‘isolated.’ They are individual occurrences. One hundred fifty million Americans are expected to vote across some 180,000 precincts, with as much as 75 percent participating by mail, many in jurisdictions inexperienced with administrating such programs. 

“There are sure to be problematic incidents. Some may be honest mistakes. Some may be deliberate fraud. Some may be minor and non-impactful, while others may be significant and alter the outcome.  We don’t know what will happen, but we need and deserve full access to all the information available so we can do our best to integrate it, arrive at explanatory theories, and decide for ourselves as sovereign individuals whether there’s been any deliberate malfeasance.

“What Americans need, and what the integrity of our Republic demands, is that every incident is transparently reported and discussed so people can decide whether they’re anecdotal and inconsequential or whether, instead, they’re systemic and, more importantly, outcome-determinative.

“Democracy demands transparency. The People must be confident that the election result, whether their preferred candidate wins or loses, is legitimate. Americans have the right to examine every incident and decide for themselves what to think. Facebook’s plan to brownout information attempts to deprive us of that right. At best, it will create a miasma of suspicion and resentment. At worst, it could obscure evidence of real systemic fraud or election interference. 

“Americans should accept neither.

“We welcome everyone to join our community and decide for themselves what to read, hear, think, write, and share. Let’s #Erasebook, #Twexit and join the #Transparency2020 movement at Parler.”

Parler was founded in 2018 and has a community of over 4 million people. The platform is committed to free speech, does not mine or sell data, and does not censor content based on politics or ideology. Parler continues to stand with the People and against Technoauthoritarianism.

Parenting an Addict: Mother Tells Her Gripping Story of Unwavering Love

Pittsburgh, PA, October 2, 2020 — Like a drowning woman, Christine Naman grappled for a lifeline and choked on her harsh reality: it was time to let go of denial. The tin foil, spoons and lighters she found in her daughter’s vanity weren’t the makings of a science experiment; they were drug paraphernalia. Christine’s only solace was that she hadn’t found any needles. Three days later she did.

About Natalie is Christine’s raw, compelling story of her valiant fight to help her daughter overcome seemingly insurmountable odds. It is a gripping, cautionary tale of how, in spite of a loving family and a comfortable life, a child can end up on the wrong path, meet the wrong people and get lost in the unthinkable. 

About Natalie takes readers deep inside Christine’s emotional and mental turmoil as she grows into her new, unfortunate role as the parent of an addict. She steps on syringes left on the floor and wrestles one from the family dog’s mouth. She lives the nightmare of finding an unresponsive child on the floor and uses Narcan to revive her. She struggles and wins, struggles and loses, cries and rages. 

She chases away a drug dealer and stays up all night waiting for her missing child to come home. She rejoices during periods of recovery and hope and is devastated during relapses. When her daughter suffers, Christine suffers right along with her. But through it all, never once, does Christine ever contemplate giving up. 

At its core, About Natalie is a story of fighting for — and right alongside — the ones we love, no matter how difficult the circumstances. It’s a story of keeping the faith, battling hard and helping a child get back on the right track. It is the story of struggling, living through it all and coming out on the other, better, side.

Christine has watched a perfectly healthy daughter thrive and then succumb to the pull of substances. She has suffered the feelings of isolation, pain and humiliation that being the parent of an addict often brings. She hopes that by sharing her family’s difficult story she can bring understanding and knowledge to those who do not know the problem firsthand as well as provide comfort to those who know the nightmare of addiction all too well. 

Bestselling author Christine Pisera Naman is a wife to a beautiful man named Peter and a mother to three fantastic kids named Jason, Natalie and Trevor. In her free time, she enjoys crocheting, which she does poorly; painting, again poorly; and volunteering at her local hospital, which she hopes she does well. She is the author of the Faces of Hope series of books that are now housed in the 9/11 Memorial Museum in New York City. Her other works include Caterpillar Kisses, Christmas Lights, The Novena and The Believers. About Natalie is her heart poured onto paper. 

For the About Natalie Addiction Comfort Community, please visit www.aboutnatalieaddictioncomfort.com.

About Natalie

Publisher: HCI Books

Release Date: May 2021

ISBN-13: 978-0-7573-2385-0 (Paperback)

ISBN-13: 978-0-7573-2386-7 (ePub) 

Available from Amazon.com

###

Turn Trauma into Your Fuel to Thrive

Los Angeles, CA, October 2, 2020 — Trauma doesn’t discriminate. It can happen to anyone, anytime. And in all likelihood, COVID-19 has traumatized each and every one of us to some degree. Everybody hits a low point once in a while, and ultimately, the quality of our lives depends on our ability to process heartbreaks and catastrophes successfully. So how do we do that?

In Post-Traumatic Thriving: The Art, Science, & Stories of Resilience, world-renown expert on disasters and trauma Dr. Randall Bell interweaves science and academic research with stories of people who have not just survived, but have used their trauma as their fuel to thrive. Dr. Bell sits down with survivors of the Holocaust; murder-victim’s families; crime victims; suicide survivors; and those who’ve experienced homelessness, disasters, addictions, depression, death, divorce, disabilities, defeats and disease to explore the rare mindset of the post-traumatic thriver. 

Through this unprecedented research, Dr. Bell shares with readers stories of remarkable resilience, including the following:

• A deaf man with a glass eye invented the electric guitar and became a household name, remarkably wealthy and most importantly, happy. 

• A convicted murderer took responsibility for the damage he caused, graduated with honors from college, became a minister and turned around the hearts of the most hardened criminals.

• A girl born with cerebral palsy landed the world’s first starring role on national television and spoke at the White House three times.

• A woman hid in a basement for years and lost her entire family in the Holocaust. She eventually found true love and paints stunning artwork.

• The sister of a murder victim helped millions of women in toxic domestic relationships.

• A woman’s car crash resulted in an addiction to prescription drugs, a divorce, a loss of her children and a cot in a homeless shelter. She has rebuilt it all back and more.

• A man set to go to the Olympics had his hopes dashed by Jimmy Carter and went on to build a worldwide business empire.

Ultimately, Dr. Bell documents the science of happiness, as well as the individual styles and common thread that all post-traumatic thrivers have to emerge with a fulfilling life. When trauma hits, your most significant decision will be to dive, survive or thrive. If you choose to thrive, this book is for you.

As an economist, Dr. Randall Bell has consulted on more disasters on earth than anyone in history and is widely considered the world’s top authority in the field of post-traumatic thriving. His clients include the Federal Government, State Governments, International Tribunals, major corporations and homeowners. Dr. Bell believes that “the problem is not the problem — the problem is how we react to the problem.” 

Often called the “Master of Disaster,” Dr. Bell is squarely focused on authentic recovery and resilience. His research has been profiled on major television shows and featured in numerous magazines and the international media. More information can be found at www.posttraumaticthriving.com. 

Post-Traumatic Thriving: The Art, Science, & Stories of Resilience

Publisher: Core IQ Press

Release Date: January 1, 2021

ISBN 978-0-9967931-7-9

Available from Amazon.com and all bookstores

DECN RECEIVES SIGNIFICANT INITIAL ORDER FOR INTERNATIONAL GENVIRO! SALIVA SWIFT KITS FOR THE DETECTION OF COVID-19

first order from Indian distributor is substantially larger than expected, exceeding international launch expectations with follow-up orders from distributors in Malaysia and Indonesia anticipated

LOS ANGELES, CA—October 2, 2020 / Decision Diagnostics Corp. (OTC: DECN) www.decisiondiagnostics.co, a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters through its subsidiary Pharma Tech Solutions, Inc., today confirmed it has received its first written purchase order from an Indian distributor. The first of several expected follow-up orders is substantially larger than initially reported, and is comprised of 500,000 Genviro! Saliva Swift Kits, 50,000 Genviro! Swift Verify Kits and 7,500 Genviro! Swift Kit Meters.   

“With the company having met the target date of September 26th to have our first distributor order in place, we are quite pleased that it exceeds what was planned for based upon our initial discussions with this distributor and his dealer,” said CEO Keith Berman. “In our continuing efforts with this distributor and others, we are encouraged by their interest and based on these discussions, believe we will receive subsequent orders from Malaysia and Indonesia in the coming weeks. We are having conversations on a global scale that we feel will be bolstered by the fact that we also have signed an agreement with a US testing partner.”

DECN’s Indian distributor had this to say about the product and working together, “Genviro! will quickly become an internationally recognized leader of professionally administered Covid-19 testing kits by announcing its entrance into India with its truly rapid saliva kit. The fast Covid-19 Saliva Swift Kit developed by scientists at Pharma Tech Solutions accurately detects the Covid-19 virus in just seconds. We are pleased beyond measure to be the company deemed best suited for providing this tool in our world’s time of need.. The people of India are very fortunate to have those tests coming to them shortly,” said Shailesh P.

The company had previously announced that the Genviro! Covid-19 Saliva Swift Kits had completed repeated rigorous testing at its manufacturing and product development facility in Daegu, Korea.  Further, the company stated that it will make three retail products available for international professional use: The Genviro! Saliva Swift Kit consisting of 1 test strip, an interface sleeve adapter, one saliva collection vessel, diluent, package inserts and it will be priced at $8.95 wholesale with an MSRP of $29.95; the Genviro! Swift Kit Meter that will include 1 meter good for up to 100 test readings, an instructional video on computer media, which can also be accessed at the web site www.pharmatechdirect.com, a meter user’s guide manual, and package insert.  The meter will wholesale for $19.95 with an MSRP of $39.95 and will include a user’s manual, package insert and the aforementioned DVD containing the company’s GenViro! instructional video in English, with sub-titles in four other languages, Russian, German, French and Spanish with further adaptations of the video in Hindi and Bahasa Melayu. Finally, the third product will be our Genviro! Swift Verify Kit that will include 1 test strip, an interface sleeve adapter and package insert. This kit is designed to provide a follow up Covid-19 test should that be desired.  The Genviro! Swift Verify Kit will be priced at $6.95 wholesale with an MSRP of $24.95. 

ABOUT DECISION DIAGNOSTICS CORP

Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With newly inspired technology,  and diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $15+ billion at-home testing market. 

The company's new GenViro!™ products designed to test for Covid-19 are not yet available in the United States or Puerto Rico, but Emergency (EUA) Waivers are in process with the U.S. FDA with additional submissions to take place in the near future. The company has also signed an agreement with an FDA and CLIA certified US-based testing partner to complete testing per current FDA guidelines and continues to look forward to the FDA authorization of our EUAs.  

The same data that will be produced by the company’s new testing partner will be used for submissions to the EU and Russian Federation. We will also use data provided by our Korean partner as part of the XPrize initiative.  XPrize requires a blind samples study that provides the company with additional value.  

On September 26, 2020 the company began the launch of its international package versions of its GenViro! Saliva Swift Kits and Swift Meter.  In addition, the company reports that its distributor for the Russian Federation will be taking on the Genviro! products, and will handle registration for emergency use approval in the Russian Federation.

Forward-Looking Statements:

This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of October 2, 2020, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.